Intercell & Romark combine to hit HCV
This article was originally published in Scrip
Intercell, the Austrian vaccine technology company, has agreed to link up with Romark Laboratories, a Tampa, Florida-based company, to develop a combination hepatitis C treatment. The two companies plan to start a European Phase II trial of Intercell's investigation therapeutic HCV vaccine, IC41, in combination with Romark's antiviral thiazolide compound nitazoxanide, during the first half of 2011.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.